Home > Services > Cell & Gene Therapy Solution > Immune Cell Therapy Solution > Cell-Separation
Cell Separation
The successful development of CAR-T cell therapy necessitates a significant quantity of highly-purified and viable T cells. CAR-T immunotherapy involves the genetic engineering of T cells with chimeric antigen receptors (CARs) to specifically target and eradicate cancer cells. To facilitate pre-clinical testing on various scales and enable clinical applications, it is crucial to obtain a substantial number of T cells with high purity, recovery, and viability.
The isolation of immune cells employs diverse techniques to separate specific cell populations for both research and therapeutic purposes. Immunomagnetic cell separation is a widely used method that utilizes magnetic particles conjugated with antibodies or ligands to selectively label and separate target immune cells from a heterogeneous cell population (as shown in Figure 1). This technique enables the isolation of highly purified immune cell subsets, facilitating their characterization, functional studies, and potential applications in immunotherapy.
Figure 1. Comparison of Positive Selection and Negative Selection
AcceGen specializes in providing advanced cell enrichment technologies that serve as a robust foundation for your workflow. Our offerings enabling the efficient enrichment of diverse immune cell subsets such as T cells, natural killer (NK) cells, and regulatory T cells (Treg).
By leveraging AcceGen’s comprehensive solutions for Cell and Gene Therapy Manufacturing, you can propel your research forward with confidence, driving it closer to clinical applications. Our state-of-the-art tools and expertise empower you to bring your innovative discoveries to the forefront of Cell and Gene Therapy Manufacturing.
Application
- Provides cell isolation solutions for small to large-scale cell therapy manufacturing, ensuring efficient and reliable isolation of T cells for research and clinical applications.
- Supports in vitro drug testing and hybridoma production for antibody research.
